Rapid Clinical Updates: From Gas Station Shelf to Hospital Bed: Managing Kratom and 7-OH Toxicity and Withdrawal-Slides

Pdf Summary

This presentation reviewed kratom and 7-hydroxymitragynine (7-OH), increasingly common, largely unregulated products sold in gas stations and online. Speakers explained that kratom contains alkaloids with opioid-like activity: at low doses they may feel stimulating, while at higher doses they can produce sedation, euphoria, respiratory depression, constipation, dependence, and overdose. Clinical harms reported include agitation, tachycardia, drowsiness, vomiting, confusion, seizures, hallucinations, coma, cardiac/respiratory arrest, and liver or cardiac toxicity. Most routine urine drug screens do not detect kratom or 7-OH.<br /><br />The talk emphasized that kratom use disorder and withdrawal can resemble opioid withdrawal, though anxiety, agitation, and elevated blood pressure may be prominent. Patients often use kratom to self-treat pain, mood symptoms, fatigue, or opioid withdrawal, and polysubstance use is common. Clinicians are encouraged to ask directly about kratom because patients may not volunteer it.<br /><br />For withdrawal management, buprenorphine was presented as the most evidence-supported treatment, using standard opioid withdrawal principles and the Clinical Opiate Withdrawal Scale (COWS) to guide timing. Treatment should not be delayed simply because the product is “not an opioid.” If precipitated withdrawal occurs, additional buprenorphine can be given. Methadone may be less practical because continuation after discharge can be difficult. Naltrexone is not recommended due to lack of evidence. Symptomatic treatments such as NSAIDs, acetaminophen, and sometimes gabapentin may be used as adjuncts.<br /><br />The speakers also highlighted the legal and regulatory uncertainty surrounding kratom products, especially concentrated “shots” and 7-OH formulations. Their overall message was that patients deserve compassionate, evidence-informed care, with attention to addiction treatment, discharge follow-up, naloxone co-prescribing, and support resources.

Meta Tag

Concept Kratom

Concept 7-Hydroxymitragynine

Concept Buprenorphine-Naloxone

Concept Withdrawal

Concept COWS

Keywords

Kratom

7-Hydroxymitragynine

Buprenorphine-Naloxone

Withdrawal

opioid-like effects

withdrawal management

buprenorphine

COWS

polysubstance use

naloxone

dependence

urine drug screen

COWS